Delcath Systems Inc (DCTH)

[Rapture2020]

DCTH Market Cap: $5.2M. SMH.

Anyone who thinks DCTH PPS will not rally, or that current shareholders will lose everything as a result of a reverse split that may (or may not) happen is smoking crack.

Highlights from the fourth quarter of 2017 and recent weeks include:

Revenue from European sales for 2017 increased 35% to $2.7 million from $2.0 million in 2016;

Satisfaction of all obligations under the privately placed senior secured convertible notes issued to two institutional investors in June 2016;

Completed a $5.0 million capital raise in February 2018;

Modified the Special Protocol Agreement (SPA) with the U.S. Food and Drug Administration (FDA) for the Company’s Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma (OM);

Announced that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial recommended that the study continue without modification; Reported the 500th CHEMOSAT treatment in Europe;

Announced results from a multi-center analysis of Delcath’s Percutaneous Hepatic Perfusion (PHP) therapy in the peer-reviewed Journal of Surgical Oncology; largest data set outside of clinical trial showed manageable toxicity and overall median overall survival of 15.3 months, and;

Secured a commercial supply of melphalan through an agreement with Tillomed Laboratories for use with the company’s CHEMOSAT® Delivery System for Melphalan, where it is marketed in Europe for the treatment of a wide range of cancers of the liver.

Economies of Scale, ladies!




Delcath to Present at Oppenheimer 28th Annual Healthcare Conference

A live webcast of the presentation will be available at www.delcath.com/investors-events, and a replay will be available at the same address approximately one hour after the presentation for approximately 90 days.

http://www.globenewswire.com/news-release/2018/03/19/1442327/0/en/Delcath-to-Present-at-Oppenheimer-28th-Annual-Healthcare-Conference.html